Clinical Trial Update: Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

View source ↗

Summary

Real-world evidence evaluating long-term safety and efficacy of durvalumab after concurrent chemoradiation in patients with unresectable stage III non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED